CA2493490A1 - Traitement de la depression consecutive a la douleur - Google Patents

Traitement de la depression consecutive a la douleur Download PDF

Info

Publication number
CA2493490A1
CA2493490A1 CA002493490A CA2493490A CA2493490A1 CA 2493490 A1 CA2493490 A1 CA 2493490A1 CA 002493490 A CA002493490 A CA 002493490A CA 2493490 A CA2493490 A CA 2493490A CA 2493490 A1 CA2493490 A1 CA 2493490A1
Authority
CA
Canada
Prior art keywords
pain
depression
serotonin
milnacipran
dsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002493490A
Other languages
English (en)
Inventor
Srinivas G. Rao
Jay D. Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2493490A1 publication Critical patent/CA2493490A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes visant à prévenir ou à traiter la dépression atypique consécutive à la douleur (DSP), qui consistent de manière générale à administrer une quantité efficace d'un inhibiteur de réabsorption de monoamines pour traiter ou prévenir les symptômes de la DSP. Dans une forme de réalisation préférée, on administre une quantité thérapeutiquement efficace d'un composé inhibiteur double de réabsorption de sérotonine norépinéphrine (SNRI) d'un type spécifique, ou d'un sel pharmaceutiquement acceptable de celui-ci. Les composés de SNRI préférés sont des SNRI non tricycliques, dans lesquels l'inhibition de réabsorption de la sérotonine est supérieure à celle de la norépinéphrine ; et des SNRI dans lesquels l'inhibition de réabsorption de la norépinéphrine est supérieure à celle de la sérotonine. Le composé préféré est le milnacipran ou un bio-équivalent ou un sel pharmaceutiquement acceptable de celui-ci. D'autres composés préférés sont la duloxetine et la venlafaxine, ou un bio-équivalent ou un sel pharmaceutiquement acceptable de celles-ci. Dans une autre forme de réalisation, on administre une quantité thérapeutiquement efficace d'un composé inhibiteur triple de réabsorption non tricyclique ("TRI") d'un type spécifique, ou un sel pharmaceutiquement acceptable de celui-ci. Les composés TRI sont caractérisés par leur capacité à bloquer la réabsorption (et, de ce fait, à accroître les concentrations centrales) des trois monoamines cérébrales primaires, à savoir la sérotonine, la noradrénaline et la dopamine.
CA002493490A 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur Abandoned CA2493490A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39867602P 2002-07-24 2002-07-24
US60/398,676 2002-07-24
US44303503P 2003-01-28 2003-01-28
US60/443,035 2003-01-28
PCT/US2003/023088 WO2004009069A1 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Publications (1)

Publication Number Publication Date
CA2493490A1 true CA2493490A1 (fr) 2004-01-29

Family

ID=30773102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002493490A Abandoned CA2493490A1 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Country Status (6)

Country Link
EP (1) EP1545489A4 (fr)
CN (1) CN1671368A (fr)
AU (1) AU2003268020A1 (fr)
CA (1) CA2493490A1 (fr)
MX (1) MXPA05000566A (fr)
WO (1) WO2004009069A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2599478A1 (fr) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Procede de purification de la duloxetine hydrochloride
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN112500361B (zh) * 2020-12-27 2023-05-12 甘肃瀚聚药业有限公司 一种(s)-4-苯基-2-恶唑烷酮的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome

Also Published As

Publication number Publication date
EP1545489A1 (fr) 2005-06-29
EP1545489A4 (fr) 2006-08-23
WO2004009069A1 (fr) 2004-01-29
MXPA05000566A (es) 2005-08-29
CN1671368A (zh) 2005-09-21
AU2003268020A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
US7888342B2 (en) Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
US20040034101A1 (en) Treatment and prevention of depression secondary to pain (DSP)
RU2437661C2 (ru) Милнаципран в качестве средства для продолжительного лечения синдрома фибромиалгии
EP2322225B1 (fr) Inhibiteurs sélectifs de récaptage de la norépinéphrine et de la sérotonine utilisés dans le traitement du syndrome de la fibromyosite, de l'encéphalo-myélite myalgique et de la douleur
US20080096872A1 (en) Composition for Treatment of Pain Specification
US20040106681A1 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20140093592A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PT2148670E (pt) Titulação de tapentadol
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
KR20100052559A (ko) 와우성 이명의 치료를 위한 1-아미노-알킬시클로헥산 유도체
CN105848655B (zh) 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
AU2020203874B2 (en) Methods and compositions for treating depression using cyclobenzaprine
US20100081719A1 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
CA2493490A1 (fr) Traitement de la depression consecutive a la douleur
Korn et al. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline
TW200911225A (en) Methods for improving physical function in fibromyalgia
CA2973540A1 (fr) Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant
US20060217444A1 (en) Tramadol for the treatment of functional gastrointestinal disorders
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Legal Events

Date Code Title Description
FZDE Discontinued